The global circulating tumor cells market size is expected to reach USD 26.45 Billion by 2028 according to a new study by Polaris Market Research. The report “Circulating Tumor Cells Market Share, Size, Trends, Industry Analysis Report, By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis); By Application (Clinical/Liquid Biopsy, Research); By Product; By Specimen; By Region; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Circulating tumor cells obtained via liquid biopsies are safer, cheaper, and less invasive than other surgical biopsies as liquid biopsies are considered a valuable tool in cancer diagnosis, before and after the onset of disease. Though circulating tumor cells technology is still under research phase but used for the prognosis of several cancer forms including, breast, melanoma, lung, colon, pancreas, and glioblastoma.
In the future, doctors would have a better chance of fighting cancer via liquid biopsies, and researchers would detect circulating tumor cells before any metastatic growth happens. Currently, circulating tumor cell-based screening and analysis are at a nascent market stage. The market dominance of cell-free DNA units over circulating tumor cells in cancer diagnosis has led to less share in clinical applications. The presence of circulating tumor cells in the bloodstream indicates a risk of metastasis and emergence of tumors.
Owing to the advantages and non-invasiveness of CTCs, the market companies and concerned academic institutions are undertaking several strategic initiatives to expand of CTCs in clinical facilities. In this direction, in October 2019, Bioloidics collaborated with Genome Institute of Singapore to develop a circulating tumor assay using the company’s in-proprietary ClearCell FX1 technology.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/circulating-tumor-cells-market/request-for-sample
The research market segment is projected to witness a lucrative growth rate over the assessment period. This high market growth is due to the fact that most of the products currently being on the market are primarily designed for research settings. Some of the key products currently in the market include Target Selector Platform, Celsee PREP 400, Parsortix Technology, VTX-1, and IsoFlux CTC system.
Companies operating in the market of circulating tumor cells such as Greiner Bio-One; BioFluidica, QIAGEN; Bio-Techne Corporation; Rarecells Diagnostics, ScreenCell, Menarini Silicon Biosystems; Fluxion Biosciences, Sysmex Corporation; Miltenyi Biotec, and Biocept, Inc.
Polaris Market Research has segmented the circulating tumor cells market report on the basis of technology, application, product, specimen, and region:
Circulating Tumor Cells, Technology Outlook (Revenue – USD Million, 2016 – 2028)
- CTC Detection & Enrichment Methods
- Immunocapture (Label-based)
- Size-based Separation (Label-free)
- Density-based Separation (Label-free)
- Combined Methods (Label-free)
- CTC Direct Detection Methods
- CTC Analysis
Circulating Tumor Cells, Application Outlook (Revenue – USD Million, 2016 – 2028)
- Clinical/Liquid Biopsy
Circulating Tumor Cells, Product Outlook (Revenue – USD Million, 2016 – 2028)
- Kits & Reagents
- Blood Collection Tubes
- Devices or Systems
Circulating Tumor Cells, Specimen Outlook (Revenue – USD Million, 2016 – 2028)
- Bone Marrow
- Other Body Fluids
Circulating Tumor Cells, Regional Outlook (Revenue – USD Million, 2016 – 2028)
- North America
- Asia Pacific
- South Korea
- Central & South America
- Middle East & Africa
- Saudi Arabia
- South Africa